Details of the Drug
General Information of Drug (ID: DMX94EK)
Drug Name |
4,5-dichloro-1H-indole-2,3-dione
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
4,5-Dichloroisatin; 1677-47-0; 4,5-dichloro-1H-indole-2,3-dione; 4,5-Dichloroindoline-2,3-dione; 1H-Indole-2,3-dione, 4,5-dichloro-; 4,5-dichloro-2,3-dihydro-1H-indole-2,3-dione; 4,5-Dichlorisatin; AC1NOKZI; AC1Q3HQG; Isatin-based compound, 49; SCHEMBL734955; CHEMBL385799; CTK4D2746; BDBM22829; DTXSID90408697; MolPort-001-828-451; WWSWHYAXEFLETD-UHFFFAOYSA-N; ZINC4530445; 8556AA; 4,5-dichloro-1H-indol-2,3-dione; ANW-58782; AKOS015850110; FCH1330653; 1H-Indole-2,3-dione,4,5-dichloro-; QC-9708; MCULE-6649049490; KB-35588; SY030680
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 216.02 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||